Evidence map›Paper›PMID 41840011›Full record

ArticleCommunications medicine2026

Thymopentin enhances adenoviral oncolytic therapy by regulating macrophages and CD8

Lingkai Kong, Kua Liu, Yan Liu, Huawei Cui, Peng Wang, Jiannan Qiu, Qilei Xin, Dan Zhou, Wencui Liu, Fangkun Zhao and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lingkai Kong *State Key Laboratory of Pharmaceutical Biotechnology, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Medical School, Nanjing University, Nanjing, China.
Kua Liu *State Key Laboratory of Pharmaceutical Biotechnology, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Medical School, Nanjing University, Nanjing, China.
Yan Liu *State Key Laboratory of Pharmaceutical Biotechnology, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Medical School, Nanjing University, Nanjing, China.
Huawei Cui *State Key Laboratory of Pharmaceutical Biotechnology, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Medical School, Nanjing University, Nanjing, China.
Peng WangState Key Laboratory of Pharmaceutical Biotechnology, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Medical School, Nanjing University, Nanjing, China.ORCID http://orcid.org/0000-0003-0521-0560
Jiannan QiuState Key Laboratory of Pharmaceutical Biotechnology, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Medical School, Nanjing University, Nanjing, China.
Qilei XinJinan Microecological Biomedicine Shandong Laboratory, Jinan, China.
Dan ZhouState Key Laboratory of Pharmaceutical Biotechnology, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Medical School, Nanjing University, Nanjing, China.
Wencui LiuJinan Microecological Biomedicine Shandong Laboratory, Jinan, China.
Fangkun ZhaoJinan Microecological Biomedicine Shandong Laboratory, Jinan, China.
Junnan WuJinan Microecological Biomedicine Shandong Laboratory, Jinan, China.
Xiaosong GuState Key Laboratory of Pharmaceutical Biotechnology, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Medical School, Nanjing University, Nanjing, China. nervegu@ntu.edu.cn.ORCID http://orcid.org/0000-0002-2562-6275
Junhua WuState Key Laboratory of Pharmaceutical Biotechnology, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Medical School, Nanjing University, Nanjing, China. wujunhua@nju.edu.cn.ORCID http://orcid.org/0000-0003-4753-2648
Chunping JiangJinan Microecological Biomedicine Shandong Laboratory, Jinan, China. chunpingjiang@nju.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOncolytic viruses are cancer therapies that selectively replicate in tumors, deliver therapeutic genes, and stimulate immune responses. Combining these viruses with immune-boosting agents could enhance their effectiveness. Thymopentin (TP5), an immune-modulating peptide, may enhance the antitumour efficacy of ADV.

methodsWe tested TP5 combined with adenovirus type 5 in tumor models, measuring tumor growth and immune changes using flow cytometry and antibody-based cell depletion. A modified oncolytic adenovirus producing TP5 (ADV-TP5) was created using gene editing and tested in mice and human immune cell-engrafted tumor models. TP5 was also combined with herpes simplex virus and vaccinia virus.

resultsHere we show that combining adenovirus (ADV) with thymopentin (TP5) reprograms the tumor microenvironment and enhances antitumor efficacy in xenograft models. ADV + TP5 increases proinflammatory macrophages and cytotoxic CD8

conclusionsTP5 strengthens oncolytic virotherapy by orchestrating macrophages and CD8

Identifiers

PMID41840011
PMCPMC13136370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.